Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious infectious diseases with high unmet medical need. The company operates within the biotechnology and pharmaceutical research and development industries, with a primary emphasis on treatments for chronic and difficult-to-treat bacterial infections. Its core value proposition centers on advancing differentiated small‑molecule therapeutics designed to address limitations of existing antibiotic regimens.
The company’s lead product candidate is epetraborole, an orally administered, broad‑spectrum boron‑based antibacterial agent being developed primarily for the treatment of non‑tuberculous mycobacterial (NTM) lung disease. AN2 Therapeutics was originally founded in 2015 under the name Arsanis, Inc. and later rebranded as AN2 Therapeutics in 2021 following a strategic refocus on antibacterial therapeutics. The company is publicly traded on the NASDAQ Global Market under the ticker symbol ANTX.
Business Operations
AN2 Therapeutics operates as a single reportable operating segment focused on the research and clinical development of anti‑infective therapies. The company does not currently generate product revenue and funds its operations primarily through equity financings and public offerings, as disclosed in its SEC filings. Its activities are centered on advancing epetraborole through clinical trials, regulatory planning, and supporting translational research.
Operationally, the company conducts research and development primarily through a combination of internal management and external contract research organizations. AN2 Therapeutics holds development and commercialization rights to epetraborole, which was originally discovered by Anacor Pharmaceuticals, Inc. (later acquired by Pfizer Inc.). The company does not maintain manufacturing facilities and relies on third‑party partners for clinical manufacturing, testing, and trial execution.
Strategic Position & Investments
The strategic focus of AN2 Therapeutics is to establish epetraborole as a potentially best‑in‑class oral therapy for NTM lung disease, including infections caused by Mycobacterium avium complex (MAC). Growth initiatives are centered on advancing clinical development, generating comparative clinical data, and pursuing regulatory pathways that could support future commercialization in the United States and other major markets.
The company’s investment activity is primarily directed toward internal R&D rather than acquisitions or a diversified portfolio. Epetraborole represents the company’s principal asset, and no additional clinical‑stage subsidiaries or portfolio companies have been publicly disclosed. AN2 Therapeutics’ strategy emphasizes leveraging differentiated chemistry and mechanism‑of‑action advantages rather than broad pipeline expansion at its current stage.
Geographic Footprint
AN2 Therapeutics is headquartered in Brisbane, California, within the United States, and conducts the majority of its corporate and strategic operations domestically. Clinical development activities, including patient enrollment and trial sites, extend beyond the U.S. through international clinical research collaborations, reflecting the global prevalence of NTM lung disease.
While the company does not report material international revenue or permanent overseas facilities, its clinical programs involve regulatory and operational engagement in multiple regions. This global clinical footprint is intended to support future regulatory submissions and broaden potential market access if epetraborole receives approval.
Leadership & Governance
AN2 Therapeutics is led by an executive team with experience in infectious disease drug development and public biotechnology company operations. The leadership team emphasizes a strategy focused on disciplined clinical execution, scientific differentiation, and addressing unmet needs in serious bacterial infections.
Key executives include:
- Eric Easom – President and Chief Executive Officer
- David Queener – Chief Financial Officer
- Brendan McCarthy, M.D., Ph.D. – Chief Medical Officer
The company is governed by a board of directors with backgrounds in biotechnology, pharmaceuticals, and corporate governance. Public disclosures indicate a focus on shareholder alignment, regulatory compliance, and long‑term value creation.